Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Tohru Hasegawa

<< Previous

Bullboard Posts

Next >>

Comment by Laliberte2020on Apr 02, 2021 9:59pm

136 Views

Post# 32933109

RE:RE:RE:RE:RE:RE:RE:Tohru Hasegawa

Yes I am aware of all those interviews. In the past year, everytime Algernon got any tiny bit of nr, we saw CM on proactive, biopub , fb live, etc...On that same day. Now we had the most awaited event of the last year for this company, and we get a half page nr with missing details, then complete silence, but now he gave complementary information to some paid subscribers... I am sure some shareholders got influenced into selling with the sharp sp drop of the last trading days. I am just saying, if CM had something to say, just make it public.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec